Brief: Vicore Pharma Q2 EBIT SEK -69.8 Million
24/08/2023 07:00
Aug 24 (Reuters) - Vicore Pharma Q2 adjusted free cash flow SEK -69.1 million. * Q2 net income SEK -69.2 million * Q2 adjusted EPS SEK -0.85 * Q2 sales SEK 0 * Q2 cash & investments SEK 259.6 million
Recent news on Vicore Pharma Holding AB
See all newsBrief: Vicore Pharma Holding Q3 Net Revenues Amounted To Sek 0.6 Mln
Brief: Vicore Pharma Holding AB Phase 2B Aspire Trial Of Buloxibutid In Ipf Passes Pre-Planned Futility Analysis, On Track For Mid-2027 Topline Results
Brief: Vicore Pharma Q2 Operating Loss At SEK 150.1 Million
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 01:53 PM
Brief: Vicore Pharma Shares Start Trading In US On July 2